Tripeptidyl peptidase II serves as an alternative to impaired proteasome to maintain viral growth in the host cells

The Clinically Approved Proteasome Inhibitor PS-341 Efficiently Blocks Influenza A Virus and Vesicular Stomatitis Virus Propagation by Establishing an Antiviral State

(2010) S. E. Dudek et al.   JOURNAL OF VIROLOGY

Proteasome Inhibition In Vivo Promotes Survival in a Lethal Murine Model of Severe Acute Respiratory Syndrome

(2010) X.-Z. Ma et al.   JOURNAL OF VIROLOGY

Proteasome Activator REG  Enhances Coxsackieviral Infection by Facilitating p53 Degradation

(2010) G. Gao et al.   JOURNAL OF VIROLOGY

Protein degradation systems in viral myocarditis leading to dilated cardiomyopathy

(2009) H. Luo et al.   CARDIOVASCULAR RESEARCH

Proteasome inhibition attenuates coxsackievirus-induced myocardial damage in mice

(2008) Guang Gao et al.   AMERICAN JOURNAL OF PHYSIOLOGY-HEART AND CIRCULATORY PHYSIOLOGY

Molecular Biology and Pathogenesis of Viral Myocarditis

(2008) Mitra Esfandiarei et al.   Annual Review of Pathology-Mechanisms of Disease

Is there an alternative to the proteasome in cytosolic protein degradation?

(2008) Luis C. Antón et al.   BIOCHEMICAL SOCIETY TRANSACTIONS

Proteasome inhibitor MG132 blocks viral DNA replication and assembly of human cytomegalovirus

(2008) Marion Kaspari et al.   FEBS LETTERS

Ubiquitination Is Required for Effective Replication of Coxsackievirus B3

(2008) Xiaoning Si et al.   PLoS One